戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ic improvement in patients with hypertrophic obstructive cardiomyopathy.
2 rs in patients with symptomatic hypertrophic obstructive cardiomyopathy.
3 with refractory symptoms due to hypertrophic obstructive cardiomyopathy.
4 nical symptoms in patients with hypertrophic obstructive cardiomyopathy.
5 atients with severe symptoms of hypertrophic obstructive cardiomyopathy.
6 rease gradient in patients with hypertrophic obstructive cardiomyopathy.
7 ients with severely symptomatic hypertrophic obstructive cardiomyopathy.
8 atic treatment of patients with hypertrophic obstructive cardiomyopathy.
9  the treatment of patients with hypertrophic obstructive cardiomyopathy.
10 ranslated to 4 genes/1 ncRNA in hypertrophic obstructive cardiomyopathy, 131 genes/17 ncRNA in dilate
11 tially methylated regions: 5 in hypertrophic obstructive cardiomyopathy, 151 in dilated cardiomyopath
12 l septal ablation treatment for hypertrophic obstructive cardiomyopathy, a human model of planned myo
13 ts with refractory, symptomatic hypertrophic obstructive cardiomyopathy and significant left ventricu
14 rome, neurocardiogenic syncope, hypertrophic obstructive cardiomyopathy, and cardiac resynchronisatio
15 re, certain types of arrhythmia, hypertropic obstructive cardiomyopathy, and in patients with prior m
16 eptal reduction for symptomatic hypertrophic obstructive cardiomyopathy at our institution.
17  is evident in 12 patients with hypertrophic obstructive cardiomyopathy before septal myocardial abla
18 ruction from aortic stenosis or hypertrophic obstructive cardiomyopathy but can also suggest the diag
19 ients with severely symptomatic hypertrophic obstructive cardiomyopathy can relieve symptoms and decr
20  improved clinical outcomes for hypertrophic obstructive cardiomyopathy, dilated cardiomyopathy and h
21                         Because hypertrophic obstructive cardiomyopathy, dilated cardiomyopathy, hear
22                   Patients with hypertrophic obstructive cardiomyopathy have left ventricular (LV) di
23 LVOT) velocity in patients with hypertrophic obstructive cardiomyopathy (HCM).
24 T) obstruction in patients with hypertrophic obstructive cardiomyopathy (HOCM) both acutely and on a
25                                 Hypertrophic obstructive cardiomyopathy (HOCM) is characterized by le
26 ry are unknown in patients with hypertrophic obstructive cardiomyopathy (HOCM) undergoing extended tr
27 tomatic pediatric patients with hypertrophic obstructive cardiomyopathy (HOCM) unresponsive to medica
28 low-up results in patients with hypertrophic obstructive cardiomyopathy (HOCM) who underwent either p
29 ype negative), 10 patients with hypertrophic obstructive cardiomyopathy (HOCM), 10 patients with aort
30 tment for medication-refractory hypertrophic obstructive cardiomyopathy (HOCM), the procedure remains
31  myectomy (SM) for treatment of hypertrophic obstructive cardiomyopathy (HOCM).
32 cise tolerance in patients with hypertrophic obstructive cardiomyopathy (HOCM).
33 nfarction (MI) in patients with hypertrophic obstructive cardiomyopathy (HOCM).
34  myectomy) for the treatment of hypertrophic obstructive cardiomyopathy (HOCM).
35 utic strategy for patients with hypertrophic obstructive cardiomyopathy (HOCM).
36 roves symptoms in patients with hypertrophic obstructive cardiomyopathy (HOCM).
37 al reduction therapy (NSRT) for hypertrophic obstructive cardiomyopathy (HOCM).
38 chamber pacing in patients with hypertrophic obstructive cardiomyopathy (HOCM).
39 nse to therapy in patients with hypertrophic obstructive cardiomyopathy (HOCM).
40 ing treatment for patients with hypertrophic obstructive cardiomyopathy (HOCM).
41 tly responsible for symptoms in hypertrophic obstructive cardiomyopathy (HOCM).
42 mic LVOT obstruction, mimicking hypertrophic obstructive cardiomyopathy in humans.
43 ficacy of surgical treatment of hypertrophic obstructive cardiomyopathy in patients who are severely
44                                 Hypertrophic obstructive cardiomyopathy is an inherited myocardial di
45 s encompassing causes including hypertrophic obstructive cardiomyopathy, ischemic cardiomyopathy, dil
46                                 Hypertrophic obstructive cardiomyopathy patients (N = 874) who underw
47              Of 173 consecutive hypertrophic obstructive cardiomyopathy patients who underwent ASA, 3
48 eatment of medically refractory hypertrophic obstructive cardiomyopathy patients with severe outflow
49  in dynamic obstruction in most hypertrophic obstructive cardiomyopathy patients.
50     A subgroup of patients with hypertrophic obstructive cardiomyopathy remain severely symptomatic d
51 ients with severely symptomatic hypertrophic obstructive cardiomyopathy were entered into this trial
52  symptoms in most patients with hypertrophic obstructive cardiomyopathy who are severely symptomatic
53 atients 20 to 70 years old with hypertrophic obstructive cardiomyopathy who had surgical treatment be
54 inical outcome in patients with hypertrophic obstructive cardiomyopathy who undergo septal myectomy.
55             Fifty patients with hypertrophic obstructive cardiomyopathy who underwent nonsurgical sep
56 chain reaction in patients with hypertrophic obstructive cardiomyopathy who were undergoing transcoro
57                        Patients with HCM had obstructive cardiomyopathy with left ventricular outflow
58 y for symptomatic patients with hypertrophic obstructive cardiomyopathy with persistence of the favor